Login to Your Account



Galapagos Scores $1.35B Deal With Abbott for Arthritis Drug

By Nuala Moran
Staff Writer

Thursday, March 1, 2012
LONDON – Galapagos NV landed a deal with Abbott worth $1.35 billion, plus royalties, for its JAK1 inhibitor for rheumatoid arthritis, in an agreement the company said is the largest for a Phase II compound in the history of the industry.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription